AIDS 2022

AIDS 2022
July 29-August 02, 2022
Montreal, Canada, and virtually

The 24th International AIDS Conference.

Explore more information for Gilead HIV / AIDS therapies
Material Type
Filter by Keyword(s)

Filter results with keywords such as:

  • Name of author(s)
  • Disease state
  • Indication
  • Trial phase
  • Trial name
  • Trial date

Note: Multiple keywords can be applied at the same time.

    Results (14)

    Real-world utilization of HIV pre-exposure prophylaxis (PrEP) by cisgender and transgender individuals in the United States

    • Author(s): Tao, L
    • descovy-for-prep
    • truvada-for-prep
    • HIV / AIDS

    Concordance between laboratory serologic testing and HIV-1 RNA testing among participants who acquired HIV in the DISCOVER trial

    • Author(s): Ruane, P
    • descovy-for-prep
    • HIV / AIDS

    Lipid parameters and lipid-modifying agent use in participants initiating F/TAF or F/TDF for PrEP in the DISCOVER trial

    • Author(s): Mounzer, K
    • descovy-for-prep
    • HIV / AIDS

    Pharmacokinetics of a simplified subcutaneous lenacapavir regimen versus phase 2/3 regimen

    • Author(s): Jogiraju, V
    • lenacapavir
    • HIV / AIDS

    Flt3 agonist enhances immunogenicity of arenavirus-based vaccine vector in macaques

    • Author(s): Boopathy, A
    • other
    • HIV / AIDS

    Week 48 results of a phase 3 randomized controlled trial of B/F/TAF vs DTG + F/TDF as initial treatment in adults with HIV/HBV coinfection (ALLIANCE)

    • Author(s): Avihingsanon, A
    • biktarvy
    • HIV / AIDS

    Metabolomic and lipidomic correlates of time-to-HIV-rebound in viremic controllers treated with vesatolimod

    • Author(s): Cai, Y
    • vestalimod (gs-9620)
    • HIV / AIDS

    Impact of intrinsic and extrinsic factors on the pharmacokinetics of long-acting lenacapavir for treatment of HIV

    • Author(s): Shaik, N
    • lenacapavir
    • HIV / AIDS

    Longitudinal analysis of weight change in HIV-1 treatment-naïve and -experienced people living with HIV (PLWH) initiating/switching to an NNRTI- or INSTI-based antiretroviral therapy in four large cohort studies

    • Author(s): Robineau, O
    • biktarvy
    • descovy
    • complera
    • odefsey
    • genvoya
    • stribild
    • truvada
    • HIV / AIDS

    Resistance analysis of long-acting lenacapavir in treatment-naïve people with HIV at 54 weeks

    • Author(s): VanderVeen, E
    • lenacapavir
    • HIV / AIDS

    Simulations for once-weekly dosing of oral lenacapavir

    • Author(s): Shaik, N
    • lenacapavir
    • HIV / AIDS

    Long-term integrated analysis of B/F/TAF in treatment-naïve adults with HIV through five years of follow-up

    • Author(s): Sax, P
    • biktarvy
    • HIV / AIDS

    Resistance analysis of long-acting lenacapavir in highly treatment-experienced people with HIV after 52 weeks of treatment

    • Author(s): Margot, N
    • lenacapavir
    • HIV / AIDS

    Injection-site reaction experience in clinical studies of people using lenacapavir for HIV treatment

    • Author(s): Kumar, P
    • lenacapavir
    • HIV / AIDS